menu

Clinical and Practical Advances in the Management of HIV

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Clinical and Practical Advances in the Management of HIV

close
0.25 credits
15 minutes
Clinical and Practical Advances in the Management of HIV
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Some two and a half decades since FDA approval of non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the management of HIV, newer versions continue to play an important therapeutic role in combination regimens. New NNRTIs are causing a stir because they can be paired with other high barrier to resistance agents. They also bring with them some other advantages associated with food intake and a possible neutral impact on lipids and weight gain. But an even more intriguing role may be on the horizon when NNRTIs are combined with emergent nucleoside reverse transcriptase translocation inhibitors (NRTTIs).

    Join us as Dr. David Wohl and Dr. Sorana Segal-Maurer take a close look at the who, what, when, and why of non-nucleoside reverse transcriptase inhibitors and their place in the current and future management of HIV.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Sorana Segal-Maurer, MD
    Director, The Dr. James J. Rahal Jr. Division of Infectious Diseases
    New York-Presbyterian Queens
    New York, NY
    Consulting Fees: Gilead Sciences, Janssen Therapeutics, ViiV
    Speakers Bureau: Gilead Sciences, Janssen Therapeutics, ViiV
    Contracted Research: Gilead Sciences

    David Alain Wohl, MD
    Professor
    University of North Carolina
    Chapel Hill, NC
    Consulting Fees: Gilead Sciences, Merck, ViiV
    Contracted Research: Gilead Sciences, Merck, ViiV

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Nick Lombardi has disclosed ownership interest in Vertex Pharmaceuticals.
    • Brian P. McDonough MD, FAAFP has nothing to disclose.
    • Tricia O’ Leary has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Summarize key advantages associated with the use of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the management of HIV-1.
    • Appraise the potential value of the investigational nucleoside reverse transcriptase translocation inhibitors (NRTTI) in adults infected with HIV-1.
  • Target Audience

    This activity is designed to meet the educational needs of infectious disease specialists, nurse practitioners, physician assistants, and nurses treating HIV patients.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Merck.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Some two and a half decades since FDA approval of non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the management of HIV, newer versions continue to play an important therapeutic role in combination regimens. New NNRTIs are causing a stir because they can be paired with other high barrier to resistance agents. They also bring with them some other advantages associated with food intake and a possible neutral impact on lipids and weight gain. But an even more intriguing role may be on the horizon when NNRTIs are combined with emergent nucleoside reverse transcriptase translocation inhibitors (NRTTIs).

    Join us as Dr. David Wohl and Dr. Sorana Segal-Maurer take a close look at the who, what, when, and why of non-nucleoside reverse transcriptase inhibitors and their place in the current and future management of HIV.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Sorana Segal-Maurer, MD
    Director, The Dr. James J. Rahal Jr. Division of Infectious Diseases
    New York-Presbyterian Queens
    New York, NY
    Consulting Fees: Gilead Sciences, Janssen Therapeutics, ViiV
    Speakers Bureau: Gilead Sciences, Janssen Therapeutics, ViiV
    Contracted Research: Gilead Sciences

    David Alain Wohl, MD
    Professor
    University of North Carolina
    Chapel Hill, NC
    Consulting Fees: Gilead Sciences, Merck, ViiV
    Contracted Research: Gilead Sciences, Merck, ViiV

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Nick Lombardi has disclosed ownership interest in Vertex Pharmaceuticals.
    • Brian P. McDonough MD, FAAFP has nothing to disclose.
    • Tricia O’ Leary has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Summarize key advantages associated with the use of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the management of HIV-1.
    • Appraise the potential value of the investigational nucleoside reverse transcriptase translocation inhibitors (NRTTI) in adults infected with HIV-1.
  • Target Audience

    This activity is designed to meet the educational needs of infectious disease specialists, nurse practitioners, physician assistants, and nurses treating HIV patients.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Merck.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Programs 5/13/21